Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    aml17-113
Previous Study | Return to List | Next Study

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04070768
Recruitment Status : Not yet recruiting
First Posted : August 27, 2019
Last Update Posted : September 16, 2019
Sponsor:
Collaborators:
Pfizer
AbbVie
Information provided by (Responsible Party):
Big Ten Cancer Research Consortium

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2021